Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2011-08-30
2011-08-30
Navarro, Albert (Department: 1645)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
Reexamination Certificate
active
08007828
ABSTRACT:
Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.
REFERENCES:
patent: 3523906 (1970-08-01), Masterman et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 4389330 (1983-06-01), Tice et al.
patent: 4853224 (1989-08-01), Wong
patent: 4997652 (1991-03-01), Wong
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5164188 (1992-11-01), Wong
patent: 5378475 (1995-01-01), Smith et al.
patent: 5443505 (1995-08-01), Wong et al.
patent: 5741329 (1998-04-01), Agrawal et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6217895 (2001-04-01), Guo et al.
patent: 6281015 (2001-08-01), Mooney et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6440460 (2002-08-01), Gurny et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6548078 (2003-04-01), Guo et al.
patent: 6585993 (2003-07-01), Donovan et al.
patent: 7691381 (2010-04-01), Hughes et al.
patent: 2002/0094943 (2002-07-01), Liew
patent: 2002/0098237 (2002-07-01), Donovan et al.
patent: 2003/0118598 (2003-06-01), Hunt
patent: WO 01/58472 (2001-02-01), None
Aoki, K.,Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations, Eur J Neurol Nov. 1999; 6(Suppl 4);S3-S10.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360; 318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316; 244-251:1981.
Coffield, J. et al.,The Site and Mechanism of Action of Botulinum Neurotoxin, Therapy With Botulinum Toxin, Ed. Jankovic J. et al., Marcel Dekker, Inc., (1994), p. 5.
Gonelle-Gispert, C. et al.,SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem J. (1999) 339:159-65.
Habermann E., et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51 (2);522-527:1988.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the Release of ]3H]Noradrenaline and [3 H]GABA From Rat Brain Homogenate, Experientia 44 (1988); 224-226.
Habermann E.,I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord, Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281; 47-56.
Harrison's Principles of Internal Medicine, edited by Anthony Fauci et al., 14.sup.th edition, published by McGraw Hill (1998).
Cheng, Cheng-Kuo et al.,Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis, Investigative Ophthalmology & Visual Science, Feb. 1995, vol. 36, No. 2, pp. 442-453.
Enyedi, Laura B. et al.,An intravitreal device providing sustained release of cyclosporine and dexamethasone, Current Eye Research, Oct. 17, 1995, pp. 549-557.
Hainsworth, Dean P. et al.,Sustained Release Intravitreal Dexamethasone, Journal of Ocular Pharmacology and Therapeutics, vol. 12, No. 1, 1996, pp. 57-63.
Kochinke, F. et al.,Biodegradable Drug Delivery System for Uveitis Treatment, Investigative Ophthalmology & Visual Science, Feb. 15, 1996, vol. 37, No. 3, 186-B98.
Neimann et al.,Clostridial nurotixons: new tools for dissecting exocytosis, Trends in Cell Biol. 4 (May 1994);179-185.
Pearce, L. B.,Pharmacologic Characterization of Botulinum Toxin for Basic Science and Medicine, Toxicon (1997) 35(9); 1373-1412 at 1393.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem (1987) 165;675-681.
Schantz, E. J. et al,Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine, Microbiol Rev. (1992) 56; 80-99.
Singh, B.,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B. R. Singh et al., Plenum Press, New York (1996).
Sloop, R. et al.,Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use, Neurology 48 (Jan. 1997);249-53.
Wiegand et al.,I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection, Naunyn-Schmiedeberg's Arch. Pharmnacol. 292 (1976); 161-165.
Hughes Patrick M.
Olejnik Orest
Allergan Inc.
Condino Debra
Gibson Hal
Nassif Claude
Navarro Albert
LandOfFree
Stabilized biodegradable neurotoxin implants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized biodegradable neurotoxin implants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized biodegradable neurotoxin implants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778119